{"id":6208,"date":"2017-10-02T10:17:10","date_gmt":"2017-10-02T10:17:10","guid":{"rendered":"http:\/\/cobrca.org\/?page_id=6208"},"modified":"2024-08-26T11:21:36","modified_gmt":"2024-08-26T11:21:36","slug":"poster-presentations","status":"publish","type":"page","link":"https:\/\/cobrca.org\/cobrca2024\/poster-presentations\/","title":{"rendered":"Poster Presentations"},"content":{"rendered":"

Poster Presentations<\/h3>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Adjuvant endocrine therapy<\/span><\/strong><\/td>\n<\/tr>\n
P01<\/td>\nSUSHI DOMAIN-CONTAINING PROTEIN 3 IS A PREDICTOR OF ENDOCRINE THERAPY RESPONSE IN BREAST CANCER
\nShorouk Makhlouf,<\/strong>\u00a0UK<\/em><\/td>\n<\/tr>\n
Breast Imaging<\/span><\/strong><\/td>\n<\/tr>\n
P02<\/td>\nRESIDUAL MICROCALCIFICATIONS AFTER NEOADJUVANT SYSTEMIC THERAPY FOR EARLY BREAST CANCER: IMPLICATIONS FOR SURGICAL PLANNING AND LONG-TERM OUTCOMES
\nJoel Allotey,<\/strong>\u00a0UK<\/em><\/td>\n<\/tr>\n
P03<\/td>\nLOCALIZATION OF NON-PALPABLE BREAST LESIONS
\nMartina Costa,<\/strong>\u00a0Italy<\/em><\/td>\n<\/tr>\n
P04<\/td>\nDIAGNOSIS OF PRIMARY AND SECONDARY BREAST LYMPHOMA: SOME CASES FROM OUR INSTITUTE AND REVIEW OF THE LITERATURE
\nMartina Costa,<\/strong>\u00a0Italy<\/em><\/td>\n<\/tr>\n
DCIS<\/span><\/strong><\/td>\n<\/tr>\n
P05<\/td>\nHOW CAN WE PREDICT UPSTAGING TO INVASIVE BREAST CANCER AFTER A BIOPSY DIAGNOSIS OF DUCTAL CARCINOMA IN SITU?
\nJulia Riggi,<\/strong>\u00a0Belgium<\/em><\/td>\n<\/tr>\n
HER2 positive breast cancer<\/span><\/strong><\/td>\n<\/tr>\n
P06<\/td>\nMAKING OUTCOME-BASED PRICING A REALITY IN THE UK \u2013 A RETROSPECTIVE COMPARISON OF COST-BASED VS OUTCOME-BASED PRICING FOR TRASTUZUMAB EMTANSINE (KADCYLA) IN METASTATIC BREAST CANCER
\nKarim El-Shakankery,<\/strong>\u00a0UK<\/em><\/td>\n<\/tr>\n
Locoregional therapy<\/span><\/strong><\/td>\n<\/tr>\n
P07<\/td>\nIMPACT OF OMITTING ROUTINE INTRAOPERATIVE FROZEN SECTION IN SENTINEL NODE BIOPSY FOR BREAST CANCER
\nYoumna Abdelaziz,<\/strong>\u00a0UK<\/em><\/td>\n<\/tr>\n
P08<\/td>\nRECONSIDERING THE NEED FOR INTRAOPERATIVE FROZEN SECTION IN SENTINEL LYMPH NODE BIOPSY FOR EARLY BREAST CANCER IN BAHRAIN
\nHussain Abdulla,<\/strong>\u00a0Bahrain<\/em><\/td>\n<\/tr>\n
P09<\/td>\nAXILLARY RECURRENCE IN NON-STANDARD VS STANDARD AXILLARY LYMPH NODE\u00a0DISSECTION IN N2-N3 HER2+ AND TRIPLE NEGATIVE BREAST CANCER PATIENTS THAT UNDERGO NEOADJUVANT SYSTEMIC THERAPY
\nSergio Aguilar-Villanueva,<\/strong>\u00a0Mexico<\/em><\/td>\n<\/tr>\n
P10<\/td>\nLOCO-REGIONAL TREATMENT IN METASTATIC BREAST CANCER
\nEmanuela Esposito,<\/strong>\u00a0Italy<\/em><\/td>\n<\/tr>\n
P11<\/td>\nLONG TERM PATIENT REPORTED OUTCOMES FOLLOWING THERAPEUTIC MAMMAPLASTY OVER 17 YEARS
\nKatherine Fairhurst,<\/strong>\u00a0UK<\/em><\/td>\n<\/tr>\n
P12<\/td>\nDOES USE OF INTRAOPERATIVE INDOCYANINE GREEN (ICG) IMAGING REDUCE THE RISK OF MASTECTOMY SKIN FLAP NECROSIS (MFN) IN IMMEDIATE DEEP INFERIOR EPIGASTRIC PERFORATOR (DIEP) BREAST RECONSTRUCTIVE SURGERY?
\nXin Yi Foong,<\/strong>\u00a0UK<\/em><\/td>\n<\/tr>\n
P13<\/td>\nSURGICAL MANAGEMENT OF THE NODE POSITIVE AXILLA WITH TARGETED AXILLARY\u00a0DISSECTION IN BREAST CANCER: A SINGLE CENTRE EXPERIENCE OVER 6 YEARS OF PRACTICE
\nChia Yin Goh,<\/strong>\u00a0UK<\/em><\/td>\n<\/tr>\n
P14<\/td>\nPOST MASTECTOMY RECONSTRUCTION PRACTICES AND OUTCOMES FOR OLDER\u00a0WOMEN IN A UK TERTIARY CARE CENTRE
\nJunaid Zia Hashmi,<\/strong>\u00a0UK<\/em><\/td>\n<\/tr>\n
P15<\/td>\nIMPLANT RECONSTRUCTION: TO MESH OR NOT TO MESH?
\nKate Homyer,<\/strong> UK<\/em><\/td>\n<\/tr>\n
P16<\/td>\nONCOLOGICAL AND COSMETIC OUTCOMES OF LOCAL PERFORATOR FLAPS IN ONCOPLASTIC BREAST SURGERY; SINGLE CENTRE EXPERIENCE IN UK
\nHuma Irshad,<\/strong> UK<\/em><\/td>\n<\/tr>\n
P17<\/td>\nARE WE PERFORMING DIFFERENT TYPES OF OPERATION IN OUR OLDER BREAST CANCER PATIENTS COMPARED TO OUR YOUNGER BREAST CANCER PATIENTS?
\nDavid John,<\/strong> UK<\/em><\/td>\n<\/tr>\n
P18<\/td>\nPOST-CHEMOTHERAPY AXILLARY CONSERVATION SURGERY – UTILITY OF PRE-OPERATIVE AXILLARY ULTRASOUND AND INTRA-OPERATIVE FROZEN SECTION
\nShalaka Joshi,<\/strong>\u00a0India<\/em><\/td>\n<\/tr>\n
P19<\/td>\nRESULTS OF THE INFLUENCE TRIAL: A STUDY COMPARING INDOCYANINE GREEN (ICG) FLUORESCENCE COMBINED WITH A STANDARD TRACER VERSUS ICG ALONE FOR SENTINEL NODE BIOPSY IN EARLY BREAST CANCER
\nRahul Kanitkar,<\/strong>\u00a0UK<\/em><\/td>\n<\/tr>\n
P20<\/td>\nCHEST WALL PERFORATOR BASED FLAPS FOR PARTIAL BREAST RECONSTRUCTION AFTER BREAST CONSERVATION SURGERY: A CASE SERIES
\nAnupama Mane,<\/strong>\u00a0India<\/em><\/td>\n<\/tr>\n
P21<\/td>\nEXPLORING THE LANDSCAPE OF LOCOREGIONAL THERAPY DE-ESCALATION IN EARLY BREAST CANCER: A SYSTEMATIC REVIEW
\nStuart Andrew McIntosh,<\/strong>\u00a0UK<\/em><\/td>\n<\/tr>\n
P22<\/td>\nBORDERLINE PHYLLODES TUMOUR IN 10-YEAR-OLD PREPUBERTAL FEMALE PRESENTING WITH NON-TENDER DISCRETE BREAST LUMP: A CASE REPORT
\nKathryn McKnight,<\/strong> Ireland<\/em><\/td>\n<\/tr>\n
P23<\/td>\nONCOLOGICAL OUTCOMES OF LARGE VOLUME PARTIAL BREAST RESECTIONS RECONSTRUCTED WITH LATTISSIMUS DORSI FLAP OR THERAPEUTIC MAMMOPLASTY
\nAnkita Nirpharake,<\/strong> India<\/em><\/td>\n<\/tr>\n
P24<\/td>\nSHOULD WE ADOPT NO CANCER ON INK? AN AUDIT OF MARGIN RE-EXCISION RATES\u00a0AGAINST ASCO AND ABS GUIDELINES
\nFrancesca Peters,<\/strong>\u00a0UK<\/em><\/td>\n<\/tr>\n
P25<\/td>\nDELAYED POST-BIOPSY TO SURGERY INTERVAL TENDS TO INCREASE AXILLARY NODAL\u00a0METASTASIS, ESPECIALLY IN EARLY BREAST CANCER PATIENTS
\nPhatcharawan Prasitviset,<\/strong>\u00a0Thailand<\/em><\/td>\n<\/tr>\n
P26<\/td>\nPIONEERING BREAST CANCER EDUCATION IN EGYPT: INSIGHTS FROM THE FIRST ADVANCED ONCOPLASTIC BREAST SURGERY SKILLS COURSE BY THE EGYPTIAN GROUP OF BREAST SURGEONS
\nIbrahim Sallam,<\/strong>\u00a0UK<\/em><\/td>\n<\/tr>\n
P27<\/td>\nADVANCING BREAST RECONSTRUCTION: LICAP FLAP OPTIMIZATION TO ACHIEVE SUPERIOR NIPPLE AND BREAST SYMMETRY
\nIbrahim Sallam,<\/strong> UK<\/em><\/td>\n<\/tr>\n
P28<\/td>\nIS COMPLETION AXILLARY NODE CLEARANCE OF ANY VALUE TO GUIDE ADJUVANT\u00a0TREATMENT CHOICE? OUTCOMES OF AN AUDIT
\nMahmoud Soliman,<\/strong>\u00a0UK<\/em><\/td>\n<\/tr>\n
P29<\/td>\nLATE TOXICITY AFTER ADJUVANT WHOLE BREAST ULTRA-HYPOFRACTIONATED RADIOTHERAPY WITH SIB: A MATCHED PAIR ANALYSIS BETWEEN OPEN CAVITY AND ONCOPLASTIC SURGERY
\nRanjan Subramani,<\/strong>\u00a0India<\/em><\/td>\n<\/tr>\n
P30<\/td>\nFLUORESCENT-GUIDED SURGERY IN ECTOPIC BREAST SURGERY: NODAL STAGING
\nAlessio Vinci,<\/strong>\u00a0U<\/em>K<\/em><\/td>\n<\/tr>\n
P31<\/td>\nRADIATION THERAPY FOR CONTRALATERAL INTERNAL MAMMARY LYPMH NODES
\nMasahiro Yoshida,<\/strong>\u00a0Japan<\/em><\/td>\n<\/tr>\n
Molecular assays<\/span><\/strong><\/td>\n<\/tr>\n
P32<\/td>\nPREDICTION OF HER2 POSITIVE BREAST CANCER PATIENTS RESPONSE TO ANTI-HER2 THERAPY USING MRNA LEVEL
\nNehal Atallah,<\/strong>\u00a0<\/span>UK<\/em><\/td>\n<\/tr>\n
P33<\/td>\nTHE IMPACT OF ONCOTYPE DX TESTING ON ADJUVANT CHEMOTHERAPY DECISION MAKING IN BREAST CANCER WITH SENTINEL LYMPH NODE MICROMETASTASIS
\nSendhil Rajan,<\/strong>\u00a0UK<\/em><\/td>\n<\/tr>\n
Neoadjuvant therapy<\/span><\/strong><\/td>\n<\/tr>\n
P34<\/td>\nMANAGEMENT OF A LYMPH NODE POSITIVE AXILLA AFTER NEO-ADJUVANT CHEMOTHERAPY FOR BREAST CANCER: A SINGLE CENTRE EXPERIENCE
\nKhalid Amin,<\/strong> UK<\/em><\/td>\n<\/tr>\n
P35<\/td>\nPATHOLOGICAL COMPLETE RESPONSE RATE AS A PROGNOSTIC FACTOR ACROSS MOLECULAR SUBTYPES OF BREAST CANCER: INSIGHTS FROM REAL WORLD DATA!
\nMitchelle Engineer,<\/strong> India<\/em><\/td>\n<\/tr>\n
P36<\/td>\nEMERGING TECHNOLOGIES FOR MONITORING BREAST CANCER RESPONSE TO NEOADJUVANT CHEMOTHERAPY: A SCOPING REVIEW
\nThomas Hubbard,<\/strong> UK<\/em><\/td>\n<\/tr>\n
P37<\/td>\nUSING RAMAN SPECTROSCOPY TO DIFFERENTIATE TREATMENT RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY IN EARLY BREAST CANCER
\nThomas Hubbard,<\/strong> UK<\/em><\/td>\n<\/tr>\n
P38<\/td>\nNEOADJUVANT ENDOCRINE THERAPY: A SINGLE CENTRE STUDY EXAMINING THE USE\u00a0OF NEOADJUVANT ENDOCRINE THERAPY IN ER+VE BREAST CANCER PATIENTS
\nHarsimran Kaur Surinder Singh,<\/strong>\u00a0UK<\/em><\/td>\n<\/tr>\n
Precision oncology<\/span><\/strong><\/td>\n<\/tr>\n
P39<\/td>\nLABEL-FREE IMPEDIMETRIC BIOSENSOR BASED ON DNA CHARACTERIZATION FOR\u00a0HUMAN SAMPLES WITH BREAST CANCER
\nLeticia Arias,<\/strong>\u00a0Mexico<\/em><\/td>\n<\/tr>\n
P40<\/td>\nMODULATORS OF RESPONSE TO TRASTUZUMAB-BASED CHEMOTHERAPY IN HER2-POSITIVE BREAST CANCER
\nNehal Atallah,<\/strong>\u00a0UK<\/em><\/td>\n<\/tr>\n
P41<\/td>\nHEMATOLOGICAL AND BIOCHEMICAL MARKERS INFLUENCING BREAST CANCER RISK AND MORTALITY: PROSPECTIVE COHORT STUDY IN THE UK BIOBANK BY MULTI-STATE MODELS
\nXiaoxi Huang,<\/strong>\u00a0China<\/em><\/td>\n<\/tr>\n
P42<\/td>\nCHARACTERISATION OF PLEOMORPHIC LOBULAR CARCINOMA: AN IMAGE ANALYSIS-ASSISTED STUDY
\nShorouk Makhlouf,<\/strong> UK<\/em><\/td>\n<\/tr>\n
P43<\/td>\nINTEGRATION OF MULTI-OMICS DATA FOR PERSONALIZED TREATMENT IN TRIPLE-NEGATIVE BREAST CANCER
\nEugenie Tseuh Tabe,<\/strong> Cameroon<\/em><\/td>\n<\/tr>\n
Prevention<\/span><\/strong><\/td>\n<\/tr>\n
P44<\/td>\nSHOULD WE BE MARKING THE AXILLA WITH DELAYED SENTINEL NODE TRACERS IN RISK REDUCING MASTECTOMIES (RRM)?
\nYoumna Abdelazi,<\/strong> UK<\/em><\/td>\n<\/tr>\n
P45<\/td>\nPATIENT PARTICIPATION IN BRIEF LIFESTYLE INTERVENTION AND UNDERSTANDING OF MODIFIABLE RISKS FACTORS IN BREAST CANCER: AGREEABLE AND EFFECTIVE?
\nKaty Homyer,<\/strong> UK<\/em><\/td>\n<\/tr>\n
P46<\/td>\nA CASE REPORT OF MALE BREAST CANCER 29 YEARS AFTER TOTAL BODY IRRADIATION FOR ACUTE LYMPHOBLASTIC LEUKAEMIA
\nKezia Summers,<\/strong> UK<\/em><\/td>\n<\/tr>\n
Screening<\/span><\/strong><\/td>\n<\/tr>\n
P47<\/td>\nUSE OF A WIRELESS RADAR LOCALISATION DEVICE TO STREAMLINE PATIENT CARE
\nGauri Babu,<\/strong>\u00a0UK<\/em><\/td>\n<\/tr>\n
P48<\/td>\nTHE IMPACT OF BREAST DENSITY NOTIFICATION ON ANXIETY IN SOUTH AUSTRALIAN\u00a0WOMEN UNDERGOING BREAST CANCER SCREENING
\nWendy Ingman,<\/strong>\u00a0Australia<\/em><\/td>\n<\/tr>\n
P49<\/td>\nREDUCING AXILLARY SURGERY IN ELDERLY PATIENTS WITH SMALL BREAST CANCERS
\nVictor Lim,<\/strong>\u00a0UK<\/em><\/td>\n<\/tr>\n
P50<\/td>\nLARGE VOLUME EXTENSIVE SAMPLING (LVES) AS FIRST LINE BIOPSY TECHNIQUE IN\u00a0SELECTED GROUP OF CASES IN BREAST SCREENING PROGRAMME
\nArchana Seth,<\/strong>\u00a0UK<\/em><\/td>\n<\/tr>\n
Symptom management<\/span><\/strong><\/td>\n<\/tr>\n
P51<\/td>\nANTIBIOTIC PROPHYLAXIS AGAINST SURGICAL SITE INFECTION FOR ELECTIVE BREAST SURGERY
\nAbdulaziz Alshamlan,<\/strong> Saudi Arabia<\/em><\/td>\n<\/tr>\n
P52<\/td>\nGYNAECOMASTIA REFERRAL PATHWAY – TIME FOR A CHANGE
\nAbdelbari Gdeh,<\/strong> UK<\/em><\/td>\n<\/tr>\n
P53<\/td>\nUSAGE OF BRACKETED MAGSEED (TWO OR MORE) FOR BREAST WIDE LOCAL EXCISION IN MULTIFOCAL OR MULTICENTRIC BREAST CANCER (MFBC\/MCBC) COMBINED WITH PARTIAL BREAST RECONSTRUCTION USING PERFORATOR FLAPS
\nAkram Girgis,<\/strong> UK<\/em><\/td>\n<\/tr>\n
P54<\/td>\nPOSTOPERATIVE COMPLICATIONS FOLLOWING BREAST AUGMENTATION MASTOPEXY\u00a0SURGERY ABROAD AND ITS IMPACT ON NATIONAL HEALTH SERVICE (CASE REVIEW)
\nAkram Girgis,<\/strong>\u00a0UK<\/em><\/td>\n<\/tr>\n
P55<\/td>\nIDENTIFYING RESEARCH PRIORITIES FOR IMPROVING INFORMATION AND SUPPORT\u00a0FOR PATIENTS UNDERGOING BREAST CANCER SURGERY: A UK PATIENT-CENTRED PRIORITY SETTING PARTNERSHIP
\nStuart McIntosh,<\/strong>\u00a0UK<\/em><\/td>\n<\/tr>\n
Triple negative breast cancer<\/span><\/strong><\/td>\n<\/tr>\n
P56<\/td>\nNAVIGATING SYNCHRONOUS BREAST AND COLON CANCER: MULTIDISCIPLINARY MANAGEMENT OF LOW ESTROGEN RECEPTOR-POSITIVE TUMOR – A CASE REPORT
\nFarah Bani-Khaled,<\/strong> Jordan<\/em><\/td>\n<\/tr>\n
P57<\/td>\nINFLAMMATORY BREAST CANCER – SINGLE CENTER EXPERIENCE IN BANGLADESH
\nSadia Siddiky,<\/strong> UK<\/em><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Poster Presentations Adjuvant endocrine therapy P01 SUSHI DOMAIN-CONTAINING PROTEIN 3 IS A PREDICTOR OF ENDOCRINE THERAPY RESPONSE IN BREAST CANCER Shorouk Makhlouf,\u00a0UK Breast Imaging P02 RESIDUAL [\u2026]<\/span><\/p>\n","protected":false},"author":12,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-6208","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/pages\/6208"}],"collection":[{"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/comments?post=6208"}],"version-history":[{"count":36,"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/pages\/6208\/revisions"}],"predecessor-version":[{"id":10218,"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/pages\/6208\/revisions\/10218"}],"wp:attachment":[{"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/media?parent=6208"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}